HANSOH PHARMA (03692): Injection of Reconnective Votutamab (HS-20093) for the treatment of osteosarcoma included in the priority review and approval process of the National Medical Products Administration
HANSOH PHARMA (03692) announced that on September 14, 2026, based on the positive results of the pivotal Phase III trial ARTEMIS-011 of HS-20093 for injection (reconnective votutamab for injection) (the Product), the indication of the Product for the treatment of osteosarcoma patients aged 12 years who have failed at least two prior lines of therapy has been included in the priority review and approval process of China's National Medical Products Administration (NMPA).
HANSOH PHARMA (03692) announced that on September 14, 2026, based on the positive results of the pivotal Phase III trial ARTEMIS-011 of HS-20093 for injection (reconnective votutamab for injection) (the product), the indication of the product for the treatment of osteosarcoma patients aged 12 years who have failed at least two prior lines of therapy has been included in the priority review and approval process of China's National Medical Products Administration (NMPA).
Related Articles
TAIMEI TECH (02576) repurchased 20,000 shares for HK$99,200 on September 23.
YSB (09885) repurchased 141,600 shares for HK$486,900 on September 23.
Xiamen Jihong Package Technology (02603) received a pledge of 7.6 million shares and a release of pledge of 7.6 million shares from controlling shareholder and actual controller Zhuang Hao.
TAIMEI TECH (02576) repurchased 20,000 shares for HK$99,200 on September 23.
YSB (09885) repurchased 141,600 shares for HK$486,900 on September 23.
Xiamen Jihong Package Technology (02603) received a pledge of 7.6 million shares and a release of pledge of 7.6 million shares from controlling shareholder and actual controller Zhuang Hao.
